Eli Lilly and Company (NYSE:LLY) is Gunderson Capital Management Inc.’s Largest Position

Gunderson Capital Management Inc. increased its stake in Eli Lilly and Company (NYSE:LLY) by 1.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,497 shares of the company’s stock after buying an additional 223 shares during the quarter. Eli Lilly and Company comprises 8.4% of Gunderson Capital Management Inc.’s portfolio, making the stock its largest position. Gunderson Capital Management Inc.’s holdings in Eli Lilly and Company were worth $19,931,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of LLY. Lynx Investment Advisory purchased a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company during the 2nd quarter valued at $36,000. Morton Brown Family Wealth LLC grew its holdings in Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after acquiring an additional 15 shares in the last quarter. Unique Wealth Strategies LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $45,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $40,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on LLY shares. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Bank of America boosted their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Berenberg Bank increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Trading Up 0.2 %

LLY traded up $2.05 during trading on Wednesday, reaching $915.77. The company had a trading volume of 648,965 shares, compared to its average volume of 3,013,804. The firm’s 50-day simple moving average is $904.41 and its 200 day simple moving average is $850.31. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company has a market cap of $870.35 billion, a price-to-earnings ratio of 135.45, a PEG ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Equities research analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.